Chemical NameSARS-CoV-2 vaccine
Dosage FormInjection (intramuscular; 0.3 ml)
Drug ClassVaccines
Approval Year2020


  • For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.
Last updated on 6/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pfizer-BioNTech COVID-19 (BNT162b2) Vaccine (SARS-CoV-2 vaccine) Prescribing Information.2020Pfizer Inc., New York; BioNTech Manufacturing GmbH, Mainz, Germany
Document TitleYearSource
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.2020The New England Journal of Medicine